AR036833A1 - Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular. - Google Patents

Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular.

Info

Publication number
AR036833A1
AR036833A1 ARP020103877A ARP020103877A AR036833A1 AR 036833 A1 AR036833 A1 AR 036833A1 AR P020103877 A ARP020103877 A AR P020103877A AR P020103877 A ARP020103877 A AR P020103877A AR 036833 A1 AR036833 A1 AR 036833A1
Authority
AR
Argentina
Prior art keywords
antibodies
human
polynucleotides
preparation
join
Prior art date
Application number
ARP020103877A
Other languages
English (en)
Spanish (es)
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of AR036833A1 publication Critical patent/AR036833A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038Kidney, bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ARP020103877A 2001-10-18 2002-10-16 Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular. AR036833A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34365701P 2001-10-18 2001-10-18
US37771602P 2002-05-02 2002-05-02

Publications (1)

Publication Number Publication Date
AR036833A1 true AR036833A1 (es) 2004-10-06

Family

ID=26993561

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103877A AR036833A1 (es) 2001-10-18 2002-10-16 Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular.

Country Status (18)

Country Link
US (2) US7462696B2 (https=)
EP (1) EP1438339A4 (https=)
JP (2) JP2005528884A (https=)
KR (1) KR20050037478A (https=)
CN (1) CN1606569A (https=)
AR (1) AR036833A1 (https=)
BR (1) BR0213968A (https=)
CA (1) CA2463943A1 (https=)
CO (1) CO5370684A1 (https=)
DO (1) DOP2002000494A (https=)
HU (1) HUP0600335A2 (https=)
IL (1) IL161411A0 (https=)
MX (1) MXPA04003508A (https=)
PE (1) PE20030473A1 (https=)
PL (1) PL374304A1 (https=)
RU (1) RU2317998C2 (https=)
UY (1) UY27499A1 (https=)
WO (1) WO2003033674A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7504364B2 (en) 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
US7469076B2 (en) 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
WO2004075855A2 (en) * 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
EP1613737A4 (en) 2003-03-28 2008-12-03 Receptors Llc ARTIFICIAL RECEPTORS COMPRISING REVERSIBLE IMMOBILIZED CONSTRUCTION BLOCKS AND METHODS
EP1664778A2 (en) * 2003-09-03 2006-06-07 Receptors LLC Nanodevices employing combinatorial artificial receptors
US7884052B2 (en) 2004-09-03 2011-02-08 Receptors Llc Combinatorial artificial receptors including tether building blocks on scaffolds
EP1789792A2 (en) 2004-09-11 2007-05-30 Receptors LLC Combinatorial artificial receptors including peptide building blocks
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US20140273033A1 (en) * 2007-04-12 2014-09-18 Universiteit Hasselt Biomarkers for multiple sclerosis
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2285409B1 (en) * 2008-05-30 2016-04-20 XBiotech, Inc Il-1 alpha antibodies
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
CN106662578B (zh) * 2014-04-03 2021-11-12 艾勒詹尼斯有限责任公司 用于检测食物变态反应的肽、试剂和方法
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69120146T2 (de) * 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6297051B1 (en) * 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
AU2861695A (en) * 1994-06-15 1996-01-05 Ciba Corning Diagnostics Corp. Mn gene and protein
ES2296412T3 (es) * 1998-10-23 2008-04-16 Institute Of Virology Gen y proteina mn.
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses

Also Published As

Publication number Publication date
US20030077277A1 (en) 2003-04-24
HUP0600335A2 (en) 2006-08-28
PE20030473A1 (es) 2003-06-26
DOP2002000494A (es) 2004-05-31
JP2010260845A (ja) 2010-11-18
CA2463943A1 (en) 2003-04-24
PL374304A1 (en) 2005-10-03
US20100240100A1 (en) 2010-09-23
UY27499A1 (es) 2003-05-30
WO2003033674A3 (en) 2003-08-21
KR20050037478A (ko) 2005-04-22
MXPA04003508A (es) 2004-07-22
IL161411A0 (en) 2004-09-27
RU2317998C2 (ru) 2008-02-27
CN1606569A (zh) 2005-04-13
CO5370684A1 (es) 2004-02-27
EP1438339A2 (en) 2004-07-21
RU2004115112A (ru) 2005-04-27
WO2003033674A2 (en) 2003-04-24
EP1438339A4 (en) 2008-08-27
BR0213968A (pt) 2005-05-10
JP2005528884A (ja) 2005-09-29
US7462696B2 (en) 2008-12-09

Similar Documents

Publication Publication Date Title
AR036833A1 (es) Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular.
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
PE20050712A1 (es) Anticuerpos rg1
BR112021024544A2 (pt) Anticorpo monoclonal anti-ceacam5 e método de preparação do mesmo e uso do mesmo
MX2021009087A (es) Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1).
AR077998A1 (es) Proteinas terapeuticas de union a dll4
PE20071055A1 (es) Anticuerpos anti mn
CO6251370A2 (es) Una molecula de union cd20 humanizda que comprende un dominio variable de cadena pesada de inmunoglobulina (vh) y un dominio variable de cadena liviana de inmunoglobulina (vl) y metodos de uso de la misma
CY1109889T1 (el) Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων
AR044927A1 (es) Metodos y composiciones para tratar la artritis reumatoidea
AR063086A1 (es) Anticuerpos humanos que se unen a cxcr4 y usos de los mismos
BRPI0817427A8 (pt) anticorpo anti-bst2
AR059809A1 (es) Anticuerpos anti-5t4 y sus usos
WO2007109376A3 (en) Anti-tumor cell antigen antibody therapeutics
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
BRPI0407680A (pt) métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas
BR0116763A (pt) Anticorpos humanos especìficos para terapia seletiva do c ncer
ES2570627T3 (es) Ensayo in vitro de Ezrina para el diagnóstico del cáncer colorrectal
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
DOP2009000208A (es) Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana
ES2173910T3 (es) Anticuerpos humanizados dirigidos contra el antigeno a33.
AR128060A1 (es) Complejos polipeptídicos de unión a antígeno activados condicionalmente y métodos de uso de los mismos
MX2025004652A (es) Conjugados de farmaco-anticuerpo del cumulo de diferenciacion (cd70) y metodos de uso de los mismos
ECSP024340A (es) Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular
EA200601405A1 (ru) Гуманизированное антитело

Legal Events

Date Code Title Description
FB Suspension of granting procedure